Mesothelioma Clinical Trials Overview > Mesothelioma Clinical Trial List
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
| Conditions: | Mesothelioma |
| Start Date: | February 1, 2004 |
| Phase: | Phase II |
| Status: | Completed |
| NCT ID: | NCT00137826 |
| Study Type: | Interventional |
| Intervention: | Drug: Erlotinib|Drug: Bevacizumab |
| Study Design: | Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | Dana-Farber Cancer Institute|Massachusetts General Hospital|University of Chicago |
| Ages: | Adult|Senior |
| Enrollment: | 37 |
| Funded By: | Other |
| First Received: | August 29, 2005 |
| End Date: | July 1, 2009 |
| Last Updated: | October 30, 2009 |
| Last Verified: | October 1, 2009 |
Mesothelioma
Lawsuit Evaluation
Lawsuit Evaluation
